Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
42 hedge funds and large institutions have $106M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2016 Q2 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$65.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.7M |
| 3 |
JP Morgan Chase
New York
|
+$4.72M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$3.55M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$3.26M |
Top Sellers
RETA Hedge Fund Activity: Q2 2016 in Review
42 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2016, worth a combined $106M.
Buyers outnumbered sellers: 42 funds opened new RETA positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $65.5M.
- 42 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $106M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2016.
- 42 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2016 and 0 closed out, a net change of +42 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2016 was Novo Holdings A/S, an estimated $65.5M added.
Based on aggregated 13F filings for Q2 2016.